Eli Lilly, InnoCare Sign Deal That Could Top $3 Billion
By Fabiana Negrin OchoaChina-based biopharmaceutical company InnoCare Pharma has signed a research and license agreement with Eli Lilly that could be valued at more than $3 billion.InnoCare, a specialist in cancer and autoimmune diseases, will use its proprietary drug-discovery platform to develop…